ImmunoCellular Therapeutics (IMUCD) Short Interest Ratio & Short Volume

Short interest is the volume of ImmunoCellular Therapeutics shares that have been sold short but have not yet been covered or closed out. As of September 30th, traders have sold 100 shares of IMUCD short. Learn More on ImmunoCellular Therapeutics' current short interest.

ImmunoCellular Therapeutics saw a drop in short interest during the month of September. As of September 30th, there was short interest totaling 100 shares, a drop of 91.7% from the previous total of 1,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ImmunoCellular Therapeutics: Emmaus Life Sciences, Inc. (0.08%), Panbela Therapeutics, Inc. (0.00%), Petros Pharmaceuticals, Inc. (4.06%), Trevena, Inc. (0.38%), Sorrento Therapeutics, Inc. (0.66%), Hepion Pharmaceuticals, Inc. (0.30%), Revelation Biosciences, Inc. (7.54%), Avenue Therapeutics, Inc. (2.55%), Viracta Therapeutics, Inc. (0.04%), Syros Pharmaceuticals, Inc. (0.51%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.91 billion), Aon plc ($3.68 billion), The Clorox Company ($2.92 billion), Analog Devices, Inc. ($2.35 billion), Uber Technologies, Inc. ($2.27 billion), Moderna, Inc. ($2.14 billion), The Kroger Co. ($2.14 billion), Datadog, Inc. ($2.00 billion), Simon Property Group, Inc. ($1.85 billion), and International Flavors & Fragrances Inc. ($1.75 billion). View all of the most shorted stocks.

Short selling IMUCD is an investing strategy that aims to generate trading profit from ImmunoCellular Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for ImmunoCellular Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMUCD, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMUCD, twice per month. The most recent reporting period available is September, 30 2020.